ClinicalTrials.gg
CompletedNCT04797650THRIVE-AA2Updated Jul 3, 2023Results posted

Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)

A Phase 3 interventional study of CTP-543 matching placebo and CTP-543 in Alopecia Areata, sponsored by Concert Pharmaceuticals. Completed at 63 sites in 7 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-07-03.

Sponsored by Concert Pharmaceuticals (part of Sun Pharmaceutical Industries Limited) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
517
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing deuruxolitinib in Alopecia Areata — 2 open to participants now, 3 under way, 3 of them phase 3. Deuruxolitinib · Alopecia Areata.

Enrollment
3rd of 10
517 · median 336
Started
2021
with 2 others
Phase 3
5 of 10
2 open now
Registered
7th of 10
by date
Lead sponsor
6 of 10
Concert Pharmaceuticals

Among the 10 studies testing deuruxolitinib in Alopecia Areata, this one is the 3rd largest by enrollment, is one of 3 that started in 2021, is one of 5 in phase 3, and was the 7th registered.

Alopecia Areata

220 studies on the registry are indexed under Alopecia Areata; 61 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

2 of the 10 studies testing deuruxolitinib in Alopecia Areata are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About deuruxolitinib

Deuruxolitinib: first FDA approval 2024 (LEQSELVI). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 41 Alopecia Areata studies recruiting now, 16 (39%) set no upper age limit and 21 (51%) stop at 75 or younger; 20 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies testing deuruxolitinib in Alopecia Areata, or all of them as a file.
02

Study summary

This study evaluates the safety and effectiveness of an investigational study drug (called CTP-543) in adults (18 years and older) who have 50% or greater scalp hair loss.

03

Conditions studied

  • Alopecia Areata

Keywords

  • Alopecia
  • Hair loss
  • Hair disease
  • CTP-543
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years at the time of Screening. Total disease duration greater than 10 years is permitted.
  • At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50, at Screening and Baseline.
  • Willing to comply with the study visits and requirements of the study protocol.

Exclusion criteria

Exclusion Criteria:

  • Treatment with other medications or agents within 1 month of Baseline or during the study that may affect hair regrowth or immune response.
  • Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis anywhere on the body at Screening and/or Baseline.
  • Treatment with systemic medications within 3 months of Screening or during the study, or biologics within 6 months of Screening or during the study.
  • Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug.
  • medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
517 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants received CTP-543 matched placebo tablets, orally, twice daily (BID) for up to 24 weeks.

    Drug: CTP-543 matching placebo

  • Experimental
    CTP-543 8 mg BID

    Participants received CTP-543 8 mg tablets, orally, BID for up to 24 weeks.

    Drug: CTP-543

  • Experimental
    CTP-543 12 mg BID

    Participants received CTP-543 12 mg tablets, orally, BID for up to 24 weeks.

    Drug: CTP-543

Interventions

  • DrugCTP-543 matching placebo

    Administered as tablets.

  • Administered as tablets.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score ≤20 at Week 24

    SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Responders on the Hair Satisfaction Participants Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24

    SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Responders were defined as participants with responses of "satisfied" or "very satisfied".

    Time frame: Weeks 12, 16, 20, and 24

  2. Percentage of Participants Achieving an Absolute SALT Score of ≤20 at Weeks 4, 8, 12, 16, and 20

    SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

    Time frame: Weeks 4, 8, 12, 16, and 20

  3. Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24

    SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[post-baseline SALT score - baseline SALT score\]/baseline SALT score).

    Time frame: Baseline, Weeks 4, 8, 12, 16, 20, and 24

  4. Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20, and 24

    The CGI-I is a questionnaire that asks the clinician to evaluate the improvement or worsening of the participant's alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).

    Time frame: Weeks 12, 16, 20, and 24

  5. Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24

    The PGI-I is a self-administered questionnaire that asks the participant to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).

    Time frame: Weeks 12, 16, 20, and 24

  6. Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24

    The CGI-S is a questionnaire that asks the clinician to evaluate the symptom severity of the participant's alopecia areata at the time of assessment. The symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

    Time frame: Baseline, Weeks 12, 16, 20, and 24

  7. Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24

    The PGI-S is a self-administered questionnaire that asks the participant to evaluate the symptom severity of their alopecia areata at the time of assessment. Symptom severity was rated on a scale ranging from 1 to 7, where 1= normal, no hair loss; 2= borderline hair loss; 3= mild hair loss; 4= moderate hair loss; 5= marked hair loss; 6= severe hair loss; 7= among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

    Time frame: Baseline, Weeks 12, 16, 20, and 24

  8. Percentage of Participants Achieving at Least a 75% and 90% Relative Reduction in SALT Score From Baseline at Weeks 12 and 24

    SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Percentage of participants achieving at least a 75% and 90% relative reduction in SALT score from baseline at Weeks 12 and 24 are reported.

    Time frame: Baseline, Weeks 12, and 24

  9. Change in the Brigham Eyebrow Tool for Alopecia (BETA) Scores From Baseline at Weeks 12 and 24

    BETA is a clinician-rated scale that assesses the total eyebrow hair present. The BETA score is calculated based on hair density and surface area of each individual eyebrow of the participant, ranging from 0 to 3, where 0= no eyebrow, 1= minimal eyebrow, 2= moderate eyebrow, and 3= normal eyebrow. The BETA score is the sum of the right and left eyebrow scores, ranging from 0 to 6. Higher scores indicate less hair loss of eyebrows. A positive change from baseline indicates less hair loss of eyebrows.

    Time frame: Baseline, Weeks 12, and 24

  10. Change in the Brigham Eyelash Tool for Alopecia (BELA) Scores From Baseline at Weeks 12 and 24

    BELA is a clinician-rated scale that assesses the total eyelash hair present. The BELA is calculated based on distribution and grade values, ranging from 0 (no eyelashes) to 3 (full eyelashes). The BELA score is the sum of the individual scores for the left and right eyes, ranging from 0 to 6. Higher scores indicate less hair loss of eyelashes. A positive change from baseline indicates less hair loss of eyelashes.

    Time frame: Baseline, Weeks 12, and 24

  11. Change in the SPRO Scale From Baseline at Weeks 12, 16, 20, and 24

    SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Higher scores indicate the greater hair dissatisfaction. A negative change from baseline indicate the greater hair satisfaction.

    Time frame: Baseline, Weeks 12, 16, 20 and 24

  12. Percentage of Participants Achieving a ≥2-point Change From Baseline in the SPRO Scale at Weeks 12, 16, 20, and 24

    SPRO is a questionnaire answered by the participants and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied.

    Time frame: Weeks 12, 16, 20, and 24

  13. Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24

    The QPRO questionnaire provides additional details on key attributes of hair and helps provide context to the SPRO response. The individual items of QPRO are: Satisfied thickness hair coverage; Satisfied evenness hair coverage; How satisfied with your eyebrows; How satisfied with your eyelashes, scored on a scale ranging from 1 to 5 where 1=very satisfied, 2=satisfied, 3=neither satisfied nor dissatisfied, 4=dissatisfied, 5=very dissatisfied. Higher scores indicate the greater dissatisfaction on hair quality. A negative change from baseline indicate the greater satisfaction on hair quality.

    Time frame: Baseline, Weeks 12, 16, 20, and 24

  14. Change in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24

    HADS is questionnaire designed to assess anxiety and depression symptoms which is completed by participants. The questionnaire is comprised of two separate scales with a total of 14 items: A 7-item scale related to anxiety and 7-item scale related to depression. Each item within both scales is scored using a 4-point scale, ranging from 0 to 3 and the total scores in each scale can range from 0 to 21. Separate scores were created for anxiety and depression. A score between 0-7 is considered normal, 8-10 is mild, 11-14 is moderate, and \>14 is severe anxiety or depression. Higher scores indicate greater severity. A negative change from baseline indicates less severity.

    Time frame: Baseline and Week 24

  15. Percentage of Participants Achieving an Absolute SALT Score of ≤10 at Week 24

    SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).

    Time frame: Week 24

07

Results

Posted Jul 3, 2023

Participant flow

Participants were enrolled at study centers in Canada, France, Germany, Hungary, Poland, Spain and the United States from 10 June 2021 to 29 June 2022.

Participant flow — Overall Study
MilestonePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Started130258129
Efficacy population127249127
Safety population130256129
Completed119233120
Not completed11259
Withdrew: Reason not specified5125
Withdrew: Treatment emergent or worsening adverse event170
Withdrew: Lack of efficacy101
Withdrew: Non-compliance with study drug002
Withdrew: Lost to follow-up461

Outcome measures

PrimaryPercentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score ≤20 at Week 24

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score ≤20 at Week 24
Percentage of participantsPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Percentage of Participants Achieving an Absolute Severity of Alopecia Tool (SALT) Score ≤20 at Week 240.833.038.3
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.31 · 95% CI 0.25 to 0.37
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.36 · 95% CI 0.27 to 0.45
SecondaryPercentage of Responders on the Hair Satisfaction Participants Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24

SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Responders were defined as participants with responses of "satisfied" or "very satisfied".

Time frame:
Weeks 12, 16, 20, and 24
Reported as:
Number · Percentage of responders
Percentage of Responders on the Hair Satisfaction Participants Reported Outcome (SPRO) Scale at Weeks 12, 16, 20, and 24
Percentage of respondersPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Week 124.943.241.0
Week 164.941.045.1
Week 201.740.152.5
Week 241.746.551.7
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.38 · 95% CI 0.31 to 0.46
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.36 · 95% CI 0.26 to 0.45
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.37 · 95% CI 0.30 to 0.45
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.4 · 95% CI 0.31 to 0.50
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.39 · 95% CI 0.32 to 0.46
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.50 · 95% CI 0.41 to 0.59
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.45 · 95% CI 0.38 to 0.52
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.49 · 95% CI 0.40 to 0.58
SecondaryPercentage of Participants Achieving an Absolute SALT Score of ≤20 at Weeks 4, 8, 12, 16, and 20

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss).

Time frame:
Weeks 4, 8, 12, 16, and 20
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Absolute SALT Score of ≤20 at Weeks 4, 8, 12, 16, and 20
percentage of participantsPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Week 400.40
Week 80.82.92.4
Week 120.810.512.3
Week 160.820.221.1
Week 200.824.828.8
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = 0.3175 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0 · 95% CI -0.00 to 0.01
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = 0.1020 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.02 · 95% CI -0.00 to 0.05
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = 0.3103 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.02 · 95% CI -0.01 to 0.05
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.10 · 95% CI 0.06 to 0.14
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.12 · 95% CI 0.06 to 0.17
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.19 · 95% CI 0.14 to 0.24
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.2 · 95% CI 0.13 to 0.27
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo) · Risk difference (rd): 0.23 · 95% CI 0.18 to 0.29
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = <0.0001 (P-value was calculated by Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.27 · 95% CI 0.19 to 0.35
SecondaryRelative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Relative change (percent change) to baseline is calculated as: 100 x (\[post-baseline SALT score - baseline SALT score\]/baseline SALT score).

Time frame:
Baseline, Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Mean · percentage change
Relative Change in SALT Scores From Baseline at Weeks 4, 8, 12, 16, 20, and 24
percentage changePlacebo BIDCTP-543 8 mg BIDCTP-543 12 mg BID
Relative Change From Baseline at Week 40.4 ± 5.40-2.6 ± 10.10-3.2 ± 9.45
Relative Change From Baseline at Week 8-2.0 ± 13.41-11.5 ± 20.63-16.4 ± 23.92
Relative Change From Baseline at Week 12-0.7 ± 14.72-23.9 ± 29.06-30.3 ± 31.85
Relative Change From Baseline at Week 160.9 ± 13.19-34.3 ± 34.93-39.9 ± 35.43
Relative Change From Baseline at Week 200.4 ± 15.49-38.9 ± 37.64-47.7 ± 37.62
Relative Change From Baseline at Week 241.6 ± 16.54-44.6 ± 39.58-52.7 ± 38.44
Statistical analysis
  • Placebo BID vs CTP-543 8 mg BID · MMRM · p = 0.0039 (P-value was calculated by mixed model repeated measures (MMRM) analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Least square (ls) mean difference: -2.8 · 95% CI -4.7 to -0.9
  • Placebo BID vs CTP-543 12 mg BID · MMRM · p = 0.0027 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -3.4 · 95% CI -5.6 to -1.2
  • Placebo BID vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -9.4 · 95% CI -13.6 to -5.1
  • Placebo BID vs CTP-543 12 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -14.2 · 95% CI -19 to -9.3
  • Placebo BID vs CTP-543 8 mg BID · MMRM · p = <0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -23 · 95% CI -28.8 to -17.3
  • Placebo BID vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -29.3 · 95% CI -35.9 to -22.7
  • Placebo BID vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -34.8 · 95% CI -41.4 to -28.2
  • Placebo BID vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -40.2 · 95% CI -47.8 to -32.6
  • Placebo BID vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -38.7 · 95% CI -45.9 to -31.6
  • Placebo BID vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -46.6 · 95% CI -54.8 to -38.4
  • Placebo BID vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -45.9 · 95% CI -53.4 to -38.5
  • Placebo BID vs CTP-543 12 mg BID · MMRM · p = < 0.0001 · Ls mean difference: -52.8 · 95% CI -61.4 to -44.2
SecondaryPercentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20, and 24

The CGI-I is a questionnaire that asks the clinician to evaluate the improvement or worsening of the participant's alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).

Time frame:
Weeks 12, 16, 20, and 24
Reported as:
Number · Percentage of responders
Percentage of Responders Assessed Using the Clinician Global Impression of Improvement (CGI-I) at Weeks 12, 16, 20, and 24
Percentage of respondersPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Week 123.338.044.3
Week 163.245.052.0
Week 201.750.059.0
Week 242.554.161.7
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was calculated by cochran mantel haenszel (CMH) test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 12 mg BID · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 8 mg BID · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 12 mg BID · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 8 mg BID · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo)
  • Placebo vs CTP-543 12 mg BID · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 8 mg BID · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 12 mg BID · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
SecondaryPercentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24

The PGI-I is a self-administered questionnaire that asks the participant to evaluate the improvement or worsening of their alopecia areata as compared to the start of the study on a 7-point scale. Responses range from 1 (very much worse) to 7 (very much improved). Responders were defined as participants with responses of 6 (much improved) or 7 (very much improved).

Time frame:
Weeks 12, 16, 20, and 24
Reported as:
Number · Percentage of responders
Percentage of Responders Assessed Using the Patient Global Impression of Improvement (PGI-I) at Weeks 12, 16, 20, and 24
Percentage of respondersPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Week 123.343.349.2
Week 164.046.259.8
Week 205.848.764.4
Week 241.750.968.3
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 12 mg BID · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 8 mg BID · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 12 mg BID · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 8 mg BID · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 12 mg BID · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 8 mg BID · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
  • Placebo vs CTP-543 12 mg BID · Cochran-Mantel-Haenszel · p = < 0.0001 (P-value was calculated by CMH test stratified by baseline scalp hair loss (partial vs complete/near-complete) for responders in each treatment group compared to placebo.)
SecondaryChange in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24

The CGI-S is a questionnaire that asks the clinician to evaluate the symptom severity of the participant's alopecia areata at the time of assessment. The symptom severity was rated on a scale ranging from 1 to 7, where 1=normal, no hair loss; 2=borderline hair loss; 3=mild hair loss; 4=moderate hair loss; 5=marked hair loss; 6=severe hair loss; 7=among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

Time frame:
Baseline, Weeks 12, 16, 20, and 24
Reported as:
Mean · Score on a scale
Change in the Clinician Global Impression of Severity (CGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
Score on a scalePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Baseline6.4 ± 0.826.5 ± 0.836.4 ± 0.76
Change From Baseline at Week 120.0 ± 0.75-1.3 ± 1.45-1.5 ± 1.52
Change From Baseline at Week 160.1 ± 0.67-1.6 ± 1.61-1.8 ± 1.69
Change From Baseline at Week 20-0.0 ± 0.96-1.8 ± 1.80-2.2 ± 1.83
Change From Baseline at Week 240.1 ± 0.79-2.1 ± 1.97-2.4 ± 1.96
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.2 · 95% CI -1.5 to -1
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.4 · 95% CI -1.7 to -1.1
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.6 · 95% CI -1.9 to -1.3
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.8 · 95% CI -2.2 to -1.5
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.7 · 95% CI -2 to -1.3
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -2.1 · 95% CI -2.5 to -1.7
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -2.2 · 95% CI -2.5 to -1.8
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -2.4 · 95% CI -2.8 to -2
SecondaryChange in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24

The PGI-S is a self-administered questionnaire that asks the participant to evaluate the symptom severity of their alopecia areata at the time of assessment. Symptom severity was rated on a scale ranging from 1 to 7, where 1= normal, no hair loss; 2= borderline hair loss; 3= mild hair loss; 4= moderate hair loss; 5= marked hair loss; 6= severe hair loss; 7= among the most extreme hair loss. Higher scores indicate more hair loss. A negative change from baseline indicates less hair loss.

Time frame:
Baseline, Weeks 12, 16, 20, and 24
Reported as:
Mean · Score on a scale
Change in the Patient Global Impression of Severity (PGI-S) Scores From Baseline at Weeks 12, 16, 20, and 24
Score on a scalePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Baseline6.7 ± 0.646.6 ± 0.796.5 ± 0.78
Change From Baseline at Week 12-0.2 ± 0.97-1.6 ± 2.05-1.8 ± 1.88
Change From Baseline at Week 16-0.2 ± 1.06-1.8 ± 2.10-2.0 ± 1.90
Change From Baseline at Week 20-0.3 ± 1.26-2.0 ± 2.20-2.2 ± 1.91
Change From Baseline at Week 24-0.2 ± 1.04-2.3 ± 2.26-2.5 ± 1.98
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.4 · 95% CI -1.8 to -1
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.6 · 95% CI -2 to -1.1
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.6 · 95% CI -2 to -1.2
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.8 · 95% CI -2.3 to -1.4
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.7 · 95% CI -2.2 to -1.3
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.9 · 95% CI -2.4 to -1.5
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -2.1 · 95% CI -2.5 to -1.7
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -2.3 · 95% CI -2.8 to -1.8
SecondaryPercentage of Participants Achieving at Least a 75% and 90% Relative Reduction in SALT Score From Baseline at Weeks 12 and 24

SALT is a quantitative assessment of scalp hair loss with scores ranging in severity from 0 (no scalp hair loss) to a maximum of 100 (complete scalp hair loss). Percentage of participants achieving at least a 75% and 90% relative reduction in SALT score from baseline at Weeks 12 and 24 are reported.

Time frame:
Baseline, Weeks 12, and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving at Least a 75% and 90% Relative Reduction in SALT Score From Baseline at Weeks 12 and 24
Percentage of participantsPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
75% Relative Reduction: Week 1208.911.5
75% Relative Reduction: Week 24033.538.3
90% Relative Reduction: Week 1201.74.9
90% Relative Reduction: Week 24021.925.0
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by mantel-haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.09 · 95% CI 0.05 to 0.12
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by mantel-haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.12 · 95% CI 0.06 to 0.17
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by mantel-haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.33 · 95% CI 0.27 to 0.38
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by mantel-haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.37 · 95% CI 0.28 to 0.45
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = 0.0409 (P-value was calculated by mantel-haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.02 · 95% CI 0.00 to 0.03
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = 0.012 (P-value was calculated by mantel-haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.05 · 95% CI 0.01 to 0.09
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by mantel-haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.21 · 95% CI 0.16 to 0.26
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by mantel-haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.24 · 95% CI 0.16 to 0.31
SecondaryChange in the Brigham Eyebrow Tool for Alopecia (BETA) Scores From Baseline at Weeks 12 and 24

BETA is a clinician-rated scale that assesses the total eyebrow hair present. The BETA score is calculated based on hair density and surface area of each individual eyebrow of the participant, ranging from 0 to 3, where 0= no eyebrow, 1= minimal eyebrow, 2= moderate eyebrow, and 3= normal eyebrow. The BETA score is the sum of the right and left eyebrow scores, ranging from 0 to 6. Higher scores indicate less hair loss of eyebrows. A positive change from baseline indicates less hair loss of eyebrows.

Time frame:
Baseline, Weeks 12, and 24
Reported as:
Mean · Score on a scale
Change in the Brigham Eyebrow Tool for Alopecia (BETA) Scores From Baseline at Weeks 12 and 24
Score on a scalePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Baseline0.9 ± 1.640.7 ± 1.441.1 ± 1.65
Change From Baseline at Week 12-0.3 ± 0.930.8 ± 1.530.7 ± 1.66
Change From Baseline at Week 24-0.3 ± 1.11.2 ± 1.761.2 ± 1.81
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: 1 · 95% CI 0.7 to 1.4
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: 1.1 · 95% CI 0.7 to 1.5
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: 1.5 · 95% CI 1.1 to 1.8
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: 1.7 · 95% CI 1.3 to 2.2
SecondaryChange in the Brigham Eyelash Tool for Alopecia (BELA) Scores From Baseline at Weeks 12 and 24

BELA is a clinician-rated scale that assesses the total eyelash hair present. The BELA is calculated based on distribution and grade values, ranging from 0 (no eyelashes) to 3 (full eyelashes). The BELA score is the sum of the individual scores for the left and right eyes, ranging from 0 to 6. Higher scores indicate less hair loss of eyelashes. A positive change from baseline indicates less hair loss of eyelashes.

Time frame:
Baseline, Weeks 12, and 24
Reported as:
Mean · Score on a scale
Change in the Brigham Eyelash Tool for Alopecia (BELA) Scores From Baseline at Weeks 12 and 24
Score on a scalePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Baseline0.7 ± 1.380.9 ± 1.681.1 ± 1.83
Change From Baseline at Week 12-0.1 ± 0.910.9 ± 1.601.0 ± 1.76
Change From Baseline at Week 24-0.0 ± 0.931.4 ± 2.091.3 ± 1.97
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: 1.1 · 95% CI 0.7 to 1.5
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: 1.2 · 95% CI 0.7 to 1.6
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: 1.5 · 95% CI 1 to 2
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: 1.5 · 95% CI 1 to 2.1
SecondaryChange in the SPRO Scale From Baseline at Weeks 12, 16, 20, and 24

SPRO is a questionnaire answered by the participant and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied. Higher scores indicate the greater hair dissatisfaction. A negative change from baseline indicate the greater hair satisfaction.

Time frame:
Baseline, Weeks 12, 16, 20 and 24
Reported as:
Mean · Score on a scale
Change in the SPRO Scale From Baseline at Weeks 12, 16, 20, and 24
Score on a scalePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Baseline4.5 ± 0.854.6 ± 0.714.6 ± 0.80
Change From Baseline at Week 12-0.4 ± 1.14-1.6 ± 1.39-1.7 ± 1.33
Change From Baseline at Week 16-0.1 ± 1.10-1.6 ± 1.31-1.7 ± 1.36
Change From Baseline at Week 20-0.1 ± 0.97-1.5 ± 1.40-1.9 ± 1.38
Change From Baseline at Week 24-0.1 ± 0.93-1.6 ± 1.47-1.9 ± 1.41
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -1.2 · 95% CI -1.4 to -0.9
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -1.2 · 95% CI -1.5 to -0.9
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -1.4 · 95% CI -1.6 to -1.1
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -1.5 · 95% CI -1.8 to -1.2
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -1.4 · 95% CI -1.6 to -1.1
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -1.7 · 95% CI -2 to -1.4
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -1.5 · 95% CI -1.8 to -1.3
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, and baseline value.) · Ls mean difference: -1.8 · 95% CI -2.1 to -1.4
SecondaryPercentage of Participants Achieving a ≥2-point Change From Baseline in the SPRO Scale at Weeks 12, 16, 20, and 24

SPRO is a questionnaire answered by the participants and designed to measure how satisfied alopecia areata participants are with their hair at the time of the assessment. The responses range from 1 to 5: 1= very satisfied, 2= satisfied, 3= neither satisfied nor dissatisfied, 4= dissatisfied, and 5= very dissatisfied.

Time frame:
Weeks 12, 16, 20, and 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a ≥2-point Change From Baseline in the SPRO Scale at Weeks 12, 16, 20, and 24
Percentage of participantsPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Week 1215.650.459.0
Week 169.852.657.4
Week 209.250.463.6
Week 248.552.661.7
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.34 · 95% CI 0.25 to 0.43
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.43 · 95% CI 0.33 to 0.54
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.43 · 95% CI 0.35 to 0.51
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.47 · 95% CI 0.37 to 0.57
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.42 · 95% CI 0.34 to 0.5
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.54 · 95% CI 0.44 to 0.63
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.44 · 95% CI 0.36 to 0.52
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.52 · 95% CI 0.42 to 0.62
SecondaryChange in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24

The QPRO questionnaire provides additional details on key attributes of hair and helps provide context to the SPRO response. The individual items of QPRO are: Satisfied thickness hair coverage; Satisfied evenness hair coverage; How satisfied with your eyebrows; How satisfied with your eyelashes, scored on a scale ranging from 1 to 5 where 1=very satisfied, 2=satisfied, 3=neither satisfied nor dissatisfied, 4=dissatisfied, 5=very dissatisfied. Higher scores indicate the greater dissatisfaction on hair quality. A negative change from baseline indicate the greater satisfaction on hair quality.

Time frame:
Baseline, Weeks 12, 16, 20, and 24
Reported as:
Mean · Score on a scale
Change in the Individual Items of the Hair Quality Patient Reported Outcome (QPRO) Scale From Baseline at Weeks 12, 16, 20, and 24
Score on a scalePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Satisfied Thickness Hair Coverage: Baseline4.6 ± 0.764.6 ± 0.664.6 ± 0.83
Satisfied Thickness Hair Coverage: Change From Baseline at Week 12-0.3 ± 0.95-1.3 ± 1.20-1.4 ± 1.35
Satisfied Thickness Hair Coverage: Change From Baseline at Week 16-0.1 ± 0.91-1.3 ± 1.23-1.5 ± 1.30
Satisfied Thickness Hair Coverage: Change From Baseline at Week 20-0.1 ± 0.85-1.3 ± 1.35-1.7 ± 1.36
Satisfied Thickness Hair Coverage: Change From Baseline at Week 24-0.1 ± 0.89-1.4 ± 1.46-1.6 ± 1.41
Satisfied evenness hair coverage: Baseline4.7 ± 0.614.7 ± 0.584.7 ± 0.74
Satisfied evenness hair coverage: Change From Baseline at Week 12-0.3 ± 0.78-1.2 ± 1.10-1.3 ± 1.26
Satisfied evenness hair coverage: Change From Baseline at Week 16-0.2 ± 0.82-1.1 ± 1.12-1.3 ± 1.20
Satisfied evenness hair coverage: Change From Baseline at Week 20-0.1 ± 0.76-1.3 ± 1.27-1.5 ± 1.29
Satisfied evenness hair coverage: Change From Baseline at Week 24-0.1 ± 0.71-1.4 ± 1.36-1.6 ± 1.37
How satisfied with your eyebrows: Baseline4.3 ± 1.074.3 ± 1.164.1 ± 1.32
How satisfied with your eyebrows: Change From Baseline at Week 12-0.2 ± 0.84-1.3 ± 1.31-1.3 ± 1.42
How satisfied with your eyebrows: Change From Baseline at Week 16-0.2 ± 0.78-1.2 ± 1.28-1.4 ± 1.54
How satisfied with your eyebrows: Change From Baseline at Week 20-0.1 ± 0.78-1.4 ± 1.40-1.4 ± 1.47
How satisfied with your eyebrows: Change From Baseline at Week 24-0.1 ± 0.81-1.4 ± 1.43-1.6 ± 1.50
How satisfied with your eyelashes: Baseline4.1 ± 1.234.1 ± 1.323.8 ± 1.42
How satisfied with your eyelashes: Change From Baseline at Week 12-0.2 ± 0.72-1.1 ± 1.34-1.0 ± 1.29
How satisfied with your eyelashes: Change From Baseline at Week 16-0.2 ± 0.82-1.1 ± 1.29-1.1 ± 1.41
How satisfied with your eyelashes: Change From Baseline at Week 20-0.1 ± 0.83-1.2 ± 1.39-1.2 ± 1.31
How satisfied with your eyelashes: Change From Baseline at Week 24-0.1 ± 0.73-1.3 ± 1.41-1.3 ± 1.45
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.0 · 95% CI -1.2 to -0.8
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.1 · 95% CI -1.4 to -0.8
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.1 · 95% CI -1.3 to -0.9
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.3 · 95% CI -1.6 to -1.1
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.2 · 95% CI -1.5 to -1
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.6 · 95% CI -1.9 to -1.3
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.3 · 95% CI -1.6 to -1.1
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.5 · 95% CI -1.8 to -1.2
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.9 · 95% CI -1.1 to -0.7
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.0 · 95% CI -1.3 to -0.8
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.0 · 95% CI -1.2 to -0.7
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.2 · 95% CI -1.4 to -0.9
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.1 · 95% CI -1.3 to -0.9
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.4 · 95% CI -1.6 to -1.1
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.3 · 95% CI -1.5 to -1.0
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.5 · 95% CI -1.8 to -1.2
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.0 · 95% CI -1.3 to -0.8
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.1 · 95% CI -1.4 to -0.8
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.0 · 95% CI -1.3 to -0.8
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.3 · 95% CI -1.6 to -1
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.2 · 95% CI -1.5 to -1.0
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.4 · 95% CI -1.7 to -1.1
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.2 · 95% CI -1.5 to -1.0
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.5 · 95% CI -1.8 to -1.2
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.9 · 95% CI -1.1 to -0.7
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.9 · 95% CI -1.2 to -0.7
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -0.9 · 95% CI -1.2 to -0.7
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.1 · 95% CI -1.3 to -0.8
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.0 · 95% CI -1.3 to -0.8
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.2 · 95% CI -1.5 to -1.0
  • Placebo vs CTP-543 8 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.2 · 95% CI -1.4 to -0.9
  • Placebo vs CTP-543 12 mg BID · MMRM · p = < 0.0001 (P-value was calculated by MMRM analysis with effects for treatment, visit, treatment-by-visit interaction, baseline value, and baseline SALT score.) · Ls mean difference: -1.4 · 95% CI -1.6 to -1.1
SecondaryChange in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24

HADS is questionnaire designed to assess anxiety and depression symptoms which is completed by participants. The questionnaire is comprised of two separate scales with a total of 14 items: A 7-item scale related to anxiety and 7-item scale related to depression. Each item within both scales is scored using a 4-point scale, ranging from 0 to 3 and the total scores in each scale can range from 0 to 21. Separate scores were created for anxiety and depression. A score between 0-7 is considered normal, 8-10 is mild, 11-14 is moderate, and \>14 is severe anxiety or depression. Higher scores indicate greater severity. A negative change from baseline indicates less severity.

Time frame:
Baseline and Week 24
Reported as:
Mean · Score on a scale
Change in the Anxiety and Depression Scale Scores of the Hospital Anxiety and Depression Scale (HADS) From Baseline at Week 24
Score on a scalePlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Anxiety: Baseline6.2 ± 3.996.4 ± 4.216.2 ± 3.79
Anxiety: Change From Baseline at Week 24-0.6 ± 2.74-1.1 ± 3.00-0.8 ± 2.85
Depression: Baseline4.7 ± 3.964.2 ± 3.664.3 ± 3.56
Depression: Change From Baseline at Week 24-0.6 ± 2.97-1.2 ± 3.16-1.5 ± 2.60
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · ANCOVA · p = 0.1206 (P-value was calculated by analysis of covariance (ANCOVA) analysis with effects for treatment, visit, baseline SALT score, and baseline HADS value.) · Ls mean difference: 0.5 · 95% CI -0.1 to 1.0
  • Placebo vs CTP-543 12 mg BID · ANCOVA · p = 0.5367 (P-value was calculated by ANCOVA analysis with effects for treatment, visit, baseline SALT score, and baseline HADS value.) · Ls mean difference: 0.2 · 95% CI -0.5 to 0.9
  • Placebo vs CTP-543 8 mg BID · ANCOVA · p = 0.0064 (P-value was calculated by ANCOVA analysis with effects for treatment, visit, baseline SALT score, and baseline HADS value.) · Ls mean difference: 0.8 · 95% CI 0.2 to 1.3
  • Placebo vs CTP-543 12 mg BID · ANCOVA · p = 0.0011 (P-value was calculated by ANCOVA analysis with effects for treatment, visit, baseline SALT score, and baseline HADS value.) · Ls mean difference: 1.1 · 95% CI 0.4 to 1.7
SecondaryPercentage of Participants Achieving an Absolute SALT Score of ≤10 at Week 24

SALT is a quantitative assessment of scalp hair loss with scores ranging from 0 (no scalp hair loss) to 100 (complete scalp hair loss).

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an Absolute SALT Score of ≤10 at Week 24
Percentage of participantsPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Percentage of Participants Achieving an Absolute SALT Score of ≤10 at Week 24024.926.7
Statistical analysis
  • Placebo vs CTP-543 8 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.24 · 95% CI 0.19 to 0.3
  • Placebo vs CTP-543 12 mg BID · Mantel Haenszel · p = < 0.0001 (P-value was calculated by the Mantel-Haenszel estimate stratified by baseline scalp hair loss (partial vs complete/near-complete) for each treatment group compared to placebo.) · Risk difference (rd): 0.25 · 95% CI 0.18 to 0.33

Adverse events

Collected over All-cause mortality: Randomization up to Week 28; Adverse events: From first dose of study drug up to last follow up visit (Week 28). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/130 (0%)0/130 (0%)60/130 (46.2%)
CTP-543 8 mg BID0/258 (0%)3/256 (1.2%)137/256 (53.5%)
CTP-543 12 mg BID0/129 (0%)2/129 (1.6%)67/129 (51.9%)
Most frequent serious events
Most frequent serious events
EventPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
Radius fractureInjury, poisoning and procedural complications0/1300/2561/129
OsteoarthritisMusculoskeletal and connective tissue disorders0/1300/2561/129
Migraine with auraNervous system disorders0/1301/2560/129
AppendicitisInfections and infestations0/1301/2560/129
Pneumonia influenzalInfections and infestations0/1301/2560/129
Most frequent other events
Most frequent other events
EventPlaceboCTP-543 8 mg BIDCTP-543 12 mg BID
COVID-19Infections and infestations22/13060/25624/129
Asymptomatic COVID-19Infections and infestations22/13033/25621/129
HeadacheNervous system disorders19/13032/25613/129
NasopharyngitisInfections and infestations16/13033/25616/129
Blood creatine phosphokinase increasedInvestigations4/13013/25615/129
AcneSkin and subcutaneous tissue disorders3/13023/25613/129

Baseline characteristics

All randomized participants included all participants who were randomized in the study.

Age, Continuous
Age, Continuous(years)PlaceboCTP-543 8 mg BIDCTP-543 12 mg BIDTotal
Mean39.7 ± 12.4938.4 ± 12.3039.7 ± 12.9039.0 ± 12.49
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboCTP-543 8 mg BIDCTP-543 12 mg BIDTotal
Female8817784349
Male428145168
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboCTP-543 8 mg BIDCTP-543 12 mg BIDTotal
Hispanic or Latino1123943
Not Hispanic or Latino108205111424
Unknown or Not Reported1130950
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboCTP-543 8 mg BIDCTP-543 12 mg BIDTotal
Race — American Indian or Alaska Native1506
Race — Asian74415
Race — Black or African American1017734
Race — White100203109412
Race — Other1102
Race — Not reported1128948
08

Study locations

63 sites
  • Alliance Dermatology & Mohs Center
    Phoenix, Arizona 85032, United States
  • Johnson Dermatology
    Fort Smith, Arkansas 72916, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • University of Miami Hospital
    Miami, Florida 33124, United States
  • Floridian Research Institute LLC
    Miami, Florida 33145, United States
  • MetroBoston Clinical Partners, LLC
    Brighton, Massachusetts 02135, United States
  • Clinical Research Institute of Michigan, LLC
    Chesterfield, Michigan 48087, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059, United States
  • Galen Research
    Chesterfield, Missouri 63005, United States
  • Vivida Dermatology
    Las Vegas, Nevada 89148, United States
  • The Dermatology Group P.C.
    Verona, New Jersey 07044, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Columbia University Medical Center - Department of Dermatology
    New York, New York 10032, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Dermatologists of Southwest Ohio
    Mason, Ohio 45040, United States
  • Oregon Medical Research
    Portland, Oregon 97223, United States
  • Velocity Clinical Research - Providence
    Warwick, Rhode Island 02886, United States
  • The Skin Wellness Center
    Knoxville, Tennessee 37922, United States
  • North Texas Center for Clinical Research
    Frisco, Texas 75034, United States
  • Elixir Research Group
    Houston, Texas 77077, United States
  • Progressive Clinical Research
    San Antonio, Texas 78213, United States
  • Velocity Clinical Research/Gateway
    Salt Lake City, Utah 84101, United States
  • Velocity Clinical Research/Swinyer-Woseth Dermatology
    Salt Lake City, Utah 84117, United States
  • Jordan Valley Dermatology Center
    South Jordan, Utah 84095, United States
  • The Rector and Visitors of the University of Virginia
    Charlottesville, Virginia 22903, United States
  • Care Clinic Ltd.
    Red Deer, Alberta T4N6V7, Canada
  • Medical Arts Health Research Group
    Kelowna, British Columbia V1Y 4N7, Canada
  • Kingsway Clinical Research
    Etobicoke, Ontario M8X1Y9, Canada
  • North Bay Dermatology Centre
    North Bay, Ontario P1B 3Z7, Canada
  • The Centre for Dermatology
    Richmond Hill, Ontario L4B1A5, Canada
  • Centre de Recherche Saint-Louis
    Quebec, G1W4R4, Canada
  • Centre de Recherche Dermatologique du Quebec Metropolitan
    Quebec, L4B1A5, Canada
  • Centre Hospitalier Universitaire de Nice - Hôpital Archet 2
    Nice, Alpes-maritimes 06202 CEDEX 3, France
  • Chru de Brest - Hôpital Morvan
    Brest, Finestère 29609 CEDEX, France
  • Universitaetsklinikum Tübingen
    Tübingen, Baden-württemberg 72076, Germany
  • Klinikum Rechts Der Isar, Technische Universität München
    Munich, Bayern 80802, Germany
  • Universitätsklinikum Frankfurt Klinik Für Dermatologie, Venerologie Und Allergologie
    Frankfurt am main, Hessen 60590, Germany
  • Fachklinik Bad Bentheim - Dermatologische Studienambulanz
    Bad Bentheim, Niedersachsen 48455, Germany
  • Dermatologische Studienambulanz
    Bochum, Nordrhein-Westfalen 44791, Germany
  • University Hospital Muenster
    Münster, Nordrhein-westfalen 48149, Germany
  • Clinical Research Center for Hair and Skin Science, Dept of Dermatology, Charité Universitätsmedizin Berlin
    Berlin, 10117, Germany
  • Universitätsklinikum Erlangen Hautklinik
    Erlangen, 91054, Germany
  • Pécsi Tudományegyetem Klinikai Központ, Bőr-, Nemikórtani És Onkodermatológiai Klinika
    Pécs, Baranya 7632, Hungary
  • Szte Áok Szent-Györgyi Albert Klinikai Központ Bőrgyógyászati És Allergológiai Klinika
    Szeged, Csongrád-csanád 6720, Hungary
  • Bugát Pál Kórház
    Gyöngyös, Heves 3200, Hungary
  • Semmelweis Egyetem, Általános Orvostudományi Kar, Bőr-, Nemikórtani És Bőronkológiai Klinika
    Budapest, Pest 1085, Hungary
  • Wromedica I. Bielicka, A. Strzalkowska S.C.
    Wrocław, Dolnośląskie 50-685, Poland
  • Twoja Przychodnia - Centrum Medyczne Nowa Sól
    Nowa Sól, Lubuskie 67-100, Poland
  • Etg Siedlce
    Siedlce, Mazowieckie 08-110, Poland
  • Ot.Co Clinic Klinika Osipowicz & Turkowski Sp. Z O.O.
    Warszawa, Mazowieckie 00-716, Poland
  • Rcmed Oddzial Warszawa
    Warszawa, Mazowieckie 00-892, Poland
  • Carpe Diem Centrum Medycyny Estetycznej
    Warszawa, Mazowieckie 02-664, Poland
  • Etg Warszawa
    Warszawa, Mazowieckie 02-793, Poland
  • Twoja Przychodnia - Szczecinskie Centrum Medyczne
    Szczecin, 71-434, Poland
  • Etg Skierniewice
    Skierniewice, Łódzkie 96-100, Poland
  • Hospital Del Mar
    Barcelona, Cataluña 08001, Spain
  • Hospital Santa Creu I Sant Pau
    Barcelona, Cataluña 08041, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitario Reina Sofia
    Córdoba, 14004, Spain
  • Hospital Universitario Ramón Y Cajal - Edificio Consultas Externas
    Madrid, 28034, Spain
  • Hospital Doce de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Universitario Infanta Leonor
    Madrid, 28081, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Jun 2022, 11 months.

Results were first posted in Jul 2023, 1 year after primary completion.

Of 20 phase 3 interventional studies under Alopecia Areata, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 46. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 10, 2021
First posted
Mar 15, 2021
StartActual
Jun 10, 2021
Primary completionActual
Jun 8, 2022
CompletionActual
Jun 29, 2022
Results first posted
Jul 3, 2023
Last update
Jul 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04797650
Responsible party
Sponsor
First posted
Mar 15, 2021
Start date
Jun 10, 2021
Primary completion
Jun 8, 2022
Completion
Jun 29, 2022
Results posted
Jul 3, 2023
Last update
Jul 3, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deuruxolitinib

Start the discussion